Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Amgen

Product sales increased 3% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen
 
4Q Revenues: $5.5 billion (+4%)

4Q Earnings: $1.8 billion (+39%)

FY Revenues: $6.9 billion (+35%)

FY Earnings: $21.7 billion (+8%)

Comments: Product sales increased 3% in the quarter, with growth driven by Enbrel (+8% to $1.4 billion), Sensipar(+21% to $384 million), Prolia (+21% to $380 million), Kyprolis (+63% to $148 million), and XGEVA (+10% to $356 million). Neulasta sales were down 2% to $1.2 billion, Neupogen sales were down 4% to $263 million, and Epogen sales were down 37% to $342 million, due to competition.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters